EP2342336B1
(en)
|
2008-09-05 |
2016-12-14 |
President and Fellows of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
WO2011159369A1
(en)
*
|
2010-06-14 |
2011-12-22 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of tal effector and foki fusion protein
|
US9394537B2
(en)
|
2010-12-22 |
2016-07-19 |
President And Fellows Of Harvard College |
Continuous directed evolution
|
EP3461896B1
(en)
|
2011-07-15 |
2023-11-29 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
WO2013043638A1
(en)
*
|
2011-09-23 |
2013-03-28 |
Iowa State University Research Foundation, Inc. |
Monomer architecture of tal nuclease or zinc finger nuclease for dna modification
|
EP2776560A2
(en)
|
2011-11-07 |
2014-09-17 |
The University of Western Ontario |
Endonuclease for genome editing
|
WO2013074999A1
(en)
|
2011-11-16 |
2013-05-23 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
WO2013101877A2
(en)
|
2011-12-29 |
2013-07-04 |
Iowa State University Research Foundation, Inc. |
Genetically modified plants with resistance to xanthomonas and other bacterial plant pathogens
|
EP2825190B1
(en)
*
|
2012-03-15 |
2016-11-30 |
Cellectis |
Repeat variable diresidues for targeting nucleotides
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
WO2013158309A2
(en)
*
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
EP2841581B2
(en)
|
2012-04-23 |
2023-03-08 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome engineering in plants
|
WO2013176916A1
(en)
|
2012-05-25 |
2013-11-28 |
Roman Galetto |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
US10815500B2
(en)
|
2012-06-05 |
2020-10-27 |
Cellectis |
Transcription activator-like effector (TALE) fusion protein
|
CA2877290A1
(en)
|
2012-06-19 |
2013-12-27 |
Daniel F. Voytas |
Gene targeting in plants using dna viruses
|
US9091827B2
(en)
|
2012-07-09 |
2015-07-28 |
Luxtera, Inc. |
Method and system for grating couplers incorporating perturbed waveguides
|
KR102141259B1
(ko)
|
2012-09-04 |
2020-08-05 |
셀렉티스 |
멀티―체인 키메라 항원 수용체 및 그것의 용도들
|
CN103668470B
(zh)
*
|
2012-09-12 |
2015-07-29 |
上海斯丹赛生物技术有限公司 |
一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
CN110643600A
(zh)
|
2012-10-23 |
2020-01-03 |
基因工具股份有限公司 |
用于切割靶dna的系统及其用途
|
CA2890160A1
(en)
|
2012-10-31 |
2014-05-08 |
Cellectis |
Coupling herbicide resistance with targeted insertion of transgenes in plants
|
RU2711249C2
(ru)
*
|
2012-11-01 |
2020-01-15 |
Фэктор Байосайенс Инк. |
Способы и продукты для экспрессии белков в клетках
|
EP2920319B1
(en)
|
2012-11-16 |
2020-02-19 |
Poseida Therapeutics, Inc. |
Site-specific enzymes and methods of use
|
US20160272980A1
(en)
|
2012-11-16 |
2016-09-22 |
Total Marketing Services |
Method for targeted modification of algae genomes
|
WO2014102688A1
(en)
|
2012-12-27 |
2014-07-03 |
Cellectis |
New design matrix for improvement of homology-directed gene targeting
|
WO2014118719A1
(en)
|
2013-02-01 |
2014-08-07 |
Cellectis |
Tevl chimeric endonuclease and their preferential cleavage sites
|
EP3623463B1
(en)
|
2013-02-07 |
2021-10-20 |
The General Hospital Corporation |
Tale transcriptional activators
|
WO2014128659A1
(en)
|
2013-02-21 |
2014-08-28 |
Cellectis |
Method to counter-select cells or organisms by linking loci to nuclease components
|
EP2971167B1
(en)
*
|
2013-03-14 |
2019-07-31 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
US9937207B2
(en)
*
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
CA2908403A1
(en)
|
2013-04-02 |
2014-10-09 |
Bayer Cropscience Nv |
Targeted genome engineering in eukaryotes
|
WO2014169810A1
(zh)
*
|
2013-04-16 |
2014-10-23 |
深圳华大基因科技服务有限公司 |
分离的寡核苷酸及其用途
|
CN105431532B
(zh)
|
2013-05-13 |
2021-04-06 |
瑟勒提斯公司 |
Cd19特异性嵌合抗原受体及其用途
|
KR102220382B1
(ko)
|
2013-05-13 |
2021-02-25 |
셀렉티스 |
면역요법을 위한 매우 활성인 t 세포를 조작하는 방법
|
CA2913872C
(en)
*
|
2013-05-31 |
2022-01-18 |
Cellectis |
A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof
|
CA2913871C
(en)
*
|
2013-05-31 |
2021-07-13 |
Cellectis |
A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof
|
JP2016521561A
(ja)
*
|
2013-06-14 |
2016-07-25 |
セレクティス |
植物における非トランスジェニックのゲノム編集のための方法
|
EP3013939A1
(en)
*
|
2013-06-25 |
2016-05-04 |
Cellectis |
Modified diatoms for biofuel production
|
FR3008106A1
(fr)
*
|
2013-07-05 |
2015-01-09 |
Agronomique Inst Nat Rech |
Methode d'induction d'une recombinaison meiotique ciblee
|
US10782479B2
(en)
|
2013-07-08 |
2020-09-22 |
Luxtera Llc |
Method and system for mode converters for grating couplers
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US10006011B2
(en)
*
|
2013-08-09 |
2018-06-26 |
Hiroshima University |
Polypeptide containing DNA-binding domain
|
US9359599B2
(en)
*
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
WO2015042585A1
(en)
*
|
2013-09-23 |
2015-03-26 |
Rensselaer Polytechnic Institute |
Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
|
US9476884B2
(en)
|
2013-10-04 |
2016-10-25 |
University Of Massachusetts |
Hybridization- independent labeling of repetitive DNA sequence in human chromosomes
|
CA2927965A1
(en)
*
|
2013-10-25 |
2015-04-30 |
Cellectis |
Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
|
US9834791B2
(en)
|
2013-11-07 |
2017-12-05 |
Editas Medicine, Inc. |
CRISPR-related methods and compositions with governing gRNAS
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
CN105939767B
(zh)
|
2014-01-08 |
2018-04-06 |
弗洛设计声能学公司 |
具有双声电泳腔的声电泳装置
|
US10179911B2
(en)
|
2014-01-20 |
2019-01-15 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
DK3105317T3
(en)
|
2014-02-14 |
2019-01-14 |
Cellectis |
Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
|
KR102228828B1
(ko)
|
2014-03-11 |
2021-03-16 |
셀렉티스 |
동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
|
MX370272B
(es)
|
2014-03-19 |
2019-12-09 |
Cellectis |
Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
|
CN106460009A
(zh)
|
2014-03-21 |
2017-02-22 |
小利兰·斯坦福大学托管委员会 |
无核酸酶的基因组编辑
|
EP3129473B8
(en)
|
2014-04-11 |
2020-12-23 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
AU2015277180A1
(en)
*
|
2014-06-17 |
2017-01-12 |
Poseida Therapeutics, Inc. |
A method for directing proteins to specific loci in the genome and uses thereof
|
ES2876925T3
(es)
|
2014-07-29 |
2021-11-15 |
Cellectis |
Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
EP3194432B1
(en)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
CA2959694C
(en)
|
2014-09-04 |
2023-11-21 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
WO2016077052A2
(en)
|
2014-10-22 |
2016-05-19 |
President And Fellows Of Harvard College |
Evolution of proteases
|
US11014989B2
(en)
|
2015-01-26 |
2021-05-25 |
Cellectis |
Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
|
CA2976376A1
(en)
|
2015-02-13 |
2016-08-18 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
US20160244784A1
(en)
*
|
2015-02-15 |
2016-08-25 |
Massachusetts Institute Of Technology |
Population-Hastened Assembly Genetic Engineering
|
RU2017134441A
(ru)
|
2015-03-11 |
2019-04-03 |
Селлектис |
Способы конструирования аллогенных т-клеток для повышения их персистенции и/или приживления у пациентов
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
ES2905181T3
(es)
*
|
2015-05-01 |
2022-04-07 |
Prec Biosciences Inc |
Deleción precisa de secuencias cromosómicas in vivo
|
US10752670B2
(en)
|
2015-05-20 |
2020-08-25 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
EP3929286A1
(en)
|
2015-06-17 |
2021-12-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
EP3317399B1
(en)
|
2015-06-30 |
2024-06-26 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
US10392674B2
(en)
|
2015-07-22 |
2019-08-27 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
WO2017019895A1
(en)
|
2015-07-30 |
2017-02-02 |
President And Fellows Of Harvard College |
Evolution of talens
|
CN104962523B
(zh)
|
2015-08-07 |
2018-05-25 |
苏州大学 |
一种测定非同源末端连接修复活性的方法
|
CN108495641A
(zh)
|
2015-08-11 |
2018-09-04 |
塞勒克提斯公司 |
用于靶向cd38抗原和用于cd38基因失活的工程化的用于免疫疗法的细胞
|
CN108513575A
(zh)
|
2015-10-23 |
2018-09-07 |
哈佛大学的校长及成员们 |
核碱基编辑器及其用途
|
WO2017079428A1
(en)
|
2015-11-04 |
2017-05-11 |
President And Fellows Of Harvard College |
Site specific germline modification
|
EP3429634A1
(en)
|
2016-04-15 |
2019-01-23 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
US10894093B2
(en)
|
2016-04-15 |
2021-01-19 |
Cellectis |
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
EP4219731A3
(en)
|
2016-05-18 |
2023-08-09 |
Amyris, Inc. |
Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
|
MX2018014496A
(es)
|
2016-05-26 |
2019-03-28 |
Nunhems Bv |
Plantas productoras de frutas sin semillas.
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
KR102607893B1
(ko)
|
2016-08-17 |
2023-12-01 |
몬산토 테크놀로지 엘엘씨 |
지베렐린 대사의 조작을 통해 저신장 식물의 수확량을 증가시키기 위한 방법 및 조성물
|
US10576167B2
(en)
|
2016-08-17 |
2020-03-03 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
EP3757120B8
(en)
|
2016-10-04 |
2022-06-15 |
Precision Biosciences, Inc. |
Co-stimulatory domains for use in genetically-modified cells
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
AU2017378427A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
WO2018115189A1
(en)
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
WO2018162702A1
(en)
|
2017-03-10 |
2018-09-13 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nuclease fusions for enhancing genome editing by homology-directed transgene integration
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
JP6901293B2
(ja)
*
|
2017-03-15 |
2021-07-14 |
株式会社三共 |
遊技用装置
|
SG11201908658TA
(en)
|
2017-03-23 |
2019-10-30 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
CA3058268A1
(en)
|
2017-03-31 |
2018-10-04 |
Cellectis Sa |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
CA3062698A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
CA3064014A1
(en)
|
2017-05-25 |
2018-11-29 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
JP2020530277A
(ja)
|
2017-06-30 |
2020-10-22 |
セレクティスCellectis |
反復投与のための細胞免疫療法
|
US11447809B2
(en)
|
2017-07-06 |
2022-09-20 |
President And Fellows Of Harvard College |
Evolution of tRNA synthetases
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
US11624130B2
(en)
|
2017-09-18 |
2023-04-11 |
President And Fellows Of Harvard College |
Continuous evolution for stabilized proteins
|
WO2019060631A1
(en)
*
|
2017-09-20 |
2019-03-28 |
Helix Nanotechnologies, Inc. |
EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE
|
WO2019070856A1
(en)
|
2017-10-03 |
2019-04-11 |
Precision Biosciences, Inc. |
MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
SG11202004457XA
(en)
|
2017-11-17 |
2020-06-29 |
Iovance Biotherapeutics Inc |
Til expansion from fine needle aspirates and small biopsies
|
CA3085784A1
(en)
|
2017-12-14 |
2019-06-20 |
Flodesign Sonics, Inc. |
Acoustic transducer driver and controller
|
EP3501268B1
(en)
|
2017-12-22 |
2021-09-15 |
KWS SAAT SE & Co. KGaA |
Regeneration of plants in the presence of histone deacetylase inhibitors
|
EP3508581A1
(en)
|
2018-01-03 |
2019-07-10 |
Kws Saat Se |
Regeneration of genetically modified plants
|
AU2019207409B2
(en)
|
2018-01-12 |
2023-02-23 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
WO2019149743A1
(en)
|
2018-01-30 |
2019-08-08 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
MX2020008560A
(es)
|
2018-02-15 |
2020-10-12 |
Monsanto Technology Llc |
Composiciones y metodos para mejorar los rendimientos de cultivos mediante el apilamiento de rasgos.
|
EP3545756A1
(en)
|
2018-03-28 |
2019-10-02 |
KWS SAAT SE & Co. KGaA |
Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2
|
SG11202009446TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
CN112368003A
(zh)
|
2018-04-27 |
2021-02-12 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的基因编辑及其在免疫治疗中的用途
|
MX2020011656A
(es)
|
2018-05-02 |
2021-02-26 |
Cellectis |
Trigo manipulado con elevada fibra vegetal.
|
EP3567111A1
(en)
|
2018-05-09 |
2019-11-13 |
KWS SAAT SE & Co. KGaA |
Gene for resistance to a pathogen of the genus heterodera
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
EP3806619A1
(en)
|
2018-06-15 |
2021-04-21 |
Nunhems B.V. |
Seedless watermelon plants comprising modifications in an abc transporter gene
|
US20210254087A1
(en)
|
2018-06-15 |
2021-08-19 |
KWS SAAT SE & Co. KGaA |
Methods for enhancing genome engineering efficiency
|
US20220025388A1
(en)
|
2018-06-15 |
2022-01-27 |
KWS SAAT SE & Co. KGaA |
Methods for improving genome engineering and regeneration in plant
|
CA3103500A1
(en)
|
2018-06-15 |
2019-12-19 |
KWS SAAT SE & Co. KGaA |
Methods for improving genome engineering and regeneration in plant ii
|
EP3817767A1
(en)
|
2018-07-02 |
2021-05-12 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
EP3623379A1
(en)
|
2018-09-11 |
2020-03-18 |
KWS SAAT SE & Co. KGaA |
Beet necrotic yellow vein virus (bnyvv)-resistance modifying gene
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
AU2019374761A1
(en)
|
2018-11-05 |
2021-06-10 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
TW202039829A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
改善之腫瘤反應性t細胞的選擇
|
US20220193131A1
(en)
|
2018-12-19 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
|
EP3898661A1
(en)
|
2018-12-21 |
2021-10-27 |
Precision BioSciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
WO2020157573A1
(en)
|
2019-01-29 |
2020-08-06 |
The University Of Warwick |
Methods for enhancing genome engineering efficiency
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
EP3708651A1
(en)
|
2019-03-12 |
2020-09-16 |
KWS SAAT SE & Co. KGaA |
Improving plant regeneration
|
DE112020001342T5
(de)
|
2019-03-19 |
2022-01-13 |
President and Fellows of Harvard College |
Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
|
US11427814B2
(en)
|
2019-03-26 |
2022-08-30 |
Encodia, Inc. |
Modified cleavases, uses thereof and related kits
|
AU2020247918B2
(en)
*
|
2019-03-26 |
2022-06-30 |
Encodia, Inc. |
Modified cleavases, uses thereof and related kits
|
CA3135799A1
(en)
|
2019-04-03 |
2020-10-08 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
CA3136265A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
EP3966334A1
(en)
|
2019-05-10 |
2022-03-16 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
EP3757219A1
(en)
|
2019-06-28 |
2020-12-30 |
KWS SAAT SE & Co. KGaA |
Enhanced plant regeneration and transformation by using grf1 booster gene
|
US20220273715A1
(en)
|
2019-07-25 |
2022-09-01 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
AU2020333851A1
(en)
|
2019-08-20 |
2022-03-31 |
Precision Biosciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
EP4017508A1
(en)
|
2019-08-23 |
2022-06-29 |
Sana Biotechnology, Inc. |
Cd24 expressing cells and uses thereof
|
AU2020344905A1
(en)
|
2019-09-12 |
2022-04-28 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
WO2021069387A1
(en)
|
2019-10-07 |
2021-04-15 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
US20220389381A1
(en)
|
2019-10-25 |
2022-12-08 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
CA3157872A1
(en)
|
2019-11-12 |
2021-05-20 |
Otto Torjek |
Gene for resistance to a pathogen of the genus heterodera
|
US20230148071A1
(en)
|
2019-12-03 |
2023-05-11 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
WO2021113543A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
AU2021207810A1
(en)
|
2020-01-13 |
2022-08-04 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
JP2023510916A
(ja)
|
2020-01-17 |
2023-03-15 |
サナ バイオテクノロジー,インコーポレイテッド |
遺伝子発現の制御のための安全スイッチ
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
JP2023520997A
(ja)
|
2020-03-25 |
2023-05-23 |
サナ バイオテクノロジー,インコーポレイテッド |
神経学的障害及び神経学的病態の処置のための低免疫原性神経細胞
|
CN115697044A
(zh)
|
2020-03-31 |
2023-02-03 |
艾洛生物系统有限公司 |
西瓜和其他葫芦科中内源罗汉果苷途径基因的调控
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
EP4146804A1
(en)
|
2020-05-08 |
2023-03-15 |
The Broad Institute Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
EP4149252A2
(en)
*
|
2020-05-12 |
2023-03-22 |
Factor Bioscience Inc. |
Engineered gene-editing proteins
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
EP4192875A1
(en)
|
2020-08-10 |
2023-06-14 |
Precision BioSciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
WO2022036150A1
(en)
|
2020-08-13 |
2022-02-17 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
WO2022087527A1
(en)
|
2020-10-23 |
2022-04-28 |
Elo Life Systems, Inc. |
Methods for producing vanilla plants with improved flavor and agronomic production
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
EP4262811A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
EP4019638A1
(en)
|
2020-12-22 |
2022-06-29 |
KWS SAAT SE & Co. KGaA |
Promoting regeneration and transformation in beta vulgaris
|
EP4019639A1
(en)
|
2020-12-22 |
2022-06-29 |
KWS SAAT SE & Co. KGaA |
Promoting regeneration and transformation in beta vulgaris
|
IL303473A
(en)
|
2020-12-31 |
2023-08-01 |
Sana Biotechnology Inc |
Methods and compositions for modulating CAR-T activity
|
EP4284823A1
(en)
|
2021-01-28 |
2023-12-06 |
Precision BioSciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
EP4284919A1
(en)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
WO2022204155A1
(en)
|
2021-03-23 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
AU2022263418A1
(en)
|
2021-04-19 |
2023-10-26 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
US20240141311A1
(en)
|
2021-04-22 |
2024-05-02 |
North Carolina State University |
Compositions and methods for generating male sterile plants
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
BR112023024434A2
(pt)
|
2021-05-27 |
2024-02-20 |
Sana Biotechnology Inc |
Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
EP4373270A2
(en)
|
2021-07-22 |
2024-05-29 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
CA3226942A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
EP4384544A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
EP4398915A1
(en)
|
2021-09-09 |
2024-07-17 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
AU2022371430A1
(en)
|
2021-10-19 |
2024-05-30 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
CN113980141B
(zh)
*
|
2021-10-27 |
2022-11-29 |
湖北大学 |
基于大肠杆菌素e家族dna酶的蛋白质复合物及其在人工蛋白支架中的应用
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
US11753677B2
(en)
|
2021-11-10 |
2023-09-12 |
Encodia, Inc. |
Methods for barcoding macromolecules in individual cells
|
WO2023091910A1
(en)
|
2021-11-16 |
2023-05-25 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
AU2022395500A1
(en)
|
2021-11-23 |
2024-05-23 |
Cellectis Sa |
New tale protein scaffolds with improved on-target/off-target activity ratios
|
WO2023133525A1
(en)
|
2022-01-07 |
2023-07-13 |
Precision Biosciences, Inc. |
Optimized polynucleotides for protein expression
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2024055017A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
WO2024055018A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
WO2024083579A1
(en)
|
2022-10-20 |
2024-04-25 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
WO2024097314A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
CN117344048A
(zh)
*
|
2023-09-28 |
2024-01-05 |
江苏省农业科学院 |
检测无毒基因Avr-Pik的RPA-LFD引物探针组、试剂盒及其应用
|
CN117821413A
(zh)
*
|
2023-12-15 |
2024-04-05 |
湖北大学 |
一种高进行性Pfu DNA聚合酶及其制备方法和应用
|